SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 102.69+5.5%Dec 19 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (3085)9/25/2015 1:08:41 PM
From: scaram(o)uche   of 3202
 
>> we will advance ABT-494 to Phase 3 studies with a once-daily formulation.<<

6 mg twice daily looks very good. A daily dose of 12 mg looks every bit as good as 36. Going forward with 24 once daily seems like a tiny risk.... maybe 50 patients or so, each group, and it still looks like there may be some noise. (ACR70, 12 mg, Balance-II).

Given this data, they certainly can't opt for 12 or 18 mg once daily?? From ct.gov, could only find evidence of one formulation having been tested. Guess they get warm and fuzzies from 24 mg ACR20 and trough levels of 494.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News